Michael McCaughan
The Centers for Medicare & Medicaid Services is about to make a decision that could cost Amgen Inc. and...
Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)
Listen to this article
CMS’ coverage policy on erythropoietin has huge commercial implications for Amgen and J&J. It is also a wake-up call for the rest of the industry: there are now two regulators who control the keys to success in the pharmaceutical industry.
Learn what's happening at the US FDA. On the go.
More from Clinical Trials
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
• By
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
• By
Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.
More from R&D
• By
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
• By
Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.
• By
The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.